Quick Answer
20/20 Biolabs, Inc. reported Cash and Equivalents of $1.03 million for fiscal year 2025.
20/20 Biolabs, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.03M | -42.5% |
| 2024 | $1.78M | — |
- 20/20 Biolabs, Inc. showed a decrease of -42.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, 20/20 Biolabs, Inc.’s cash and equivalents has declined by 42.5% (from $1.78 million to $1.03 million).
- The most recent figure is from 20/20 Biolabs, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: